Zimmer Biomet boosts foot-and-ankle biz with Nextremity distribution deal

Zimmer Biomet is adding to its foot-and-ankle stable with a global distribution deal for Nextremity Solutions’ deformity correction devices.

Under the agreement, Zimmer Biomet will distribute Nextremity’s implants for the correction of foot and ankle deformities, including the Nextra Hammertoe Correction System, an adjustable, two-piece hammertoe implant, and the Metatarsal Shortening System, which is a bone-cutting guide and implant in one. Zimmer Biomet will also market Nextremity’s bunion correction system and staple system, according to a statement. Financial details were not disclosed.

The Nextremity devices will complement Zimmer Biomet’s Foot and Ankle System, an implant and instrument system for the reconstruction or replacement of the ankle joint.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"The agreement helps advance our commitment to provide customers with the broadest range of cutting-edge technologies and strengthens our position in the $2 billion foot and ankle market,” said Brad Quick, general manager of Zimmer Biomet’s foot and ankle unit, in the statement.

Following the $13.4 billion acquisition that created Zimmer Biomet, the company has been reaching into its deep pockets to make M&A moves. In June, it threw down a whopping $1 billion for spinal surgery player, LDR Systems, in a bid to boost its spine division. And in July, Zimmer Biomet splashed into robotic surgery with its acquisition of France’s Medtech for about $132 million.

Read more on

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.